Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil

Tzeon Jye Chiou; Sung Pao Kung; Ruey Kuen Hsieh; San Fan; Cheng Hwai Tzeng; Chih Hsin Wei; Po Min Chen

doi:10.3109/07357909609012139

Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil

Tzeon Jye Chiou, Sung Pao Kung, Ruey Kuen Hsieh, San Fan, Cheng Hwai Tzeng, Chih Hsin Wei, Po Min Chen

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

The efficacy and toxicity of a combination of etoposide 100 mg/m²/day iv on day 2-4, leucovorin 300 mg/m²/day iv, and 5-FU 500 mg/m² day iv on day 1-5 every 4 weeks were assessed in 21 patients with advanced gastric cancer with measurable or evaluable diseases. Eight patients had an objective response, including 3 in CR. The overall response rate was 38.1% (95% CI 33.4-42.8%). Five of 8 patients who exhibited locally advanced and unresectable diseases had an objective response (2 CR, 3 PR). The response rate in patients with metastatic disease was 23.0% (95% CI 14.4-31.6%). The median progression-free interval and overall survival time were 7 and 10 months, respectively. The most frequent side effect was alopecia (Gr I/II 71.4%). No treatment-related death occurred. Modified ELF is a relatively effective and tolerable combination regimen for advanced gastric cancer and can be safely administered to elderly patients and patients with systemic diseases.

Original language	English
Pages (from-to)	197-201
Number of pages	5
Journal	Cancer Investigation
Volume	14
Issue number	3
DOIs	https://doi.org/10.3109/07357909609012139
Publication status	Published - 1996
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/07357909609012139

Cite this

@article{9b3fe827810c4eb4a4019e9fb56ed8e8,

title = "Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil",

abstract = "The efficacy and toxicity of a combination of etoposide 100 mg/m2/day iv on day 2-4, leucovorin 300 mg/m2/day iv, and 5-FU 500 mg/m2 day iv on day 1-5 every 4 weeks were assessed in 21 patients with advanced gastric cancer with measurable or evaluable diseases. Eight patients had an objective response, including 3 in CR. The overall response rate was 38.1% (95% CI 33.4-42.8%). Five of 8 patients who exhibited locally advanced and unresectable diseases had an objective response (2 CR, 3 PR). The response rate in patients with metastatic disease was 23.0% (95% CI 14.4-31.6%). The median progression-free interval and overall survival time were 7 and 10 months, respectively. The most frequent side effect was alopecia (Gr I/II 71.4%). No treatment-related death occurred. Modified ELF is a relatively effective and tolerable combination regimen for advanced gastric cancer and can be safely administered to elderly patients and patients with systemic diseases.",

author = "Chiou, {Tzeon Jye} and Kung, {Sung Pao} and Hsieh, {Ruey Kuen} and San Fan and Tzeng, {Cheng Hwai} and Wei, {Chih Hsin} and Chen, {Po Min}",

note = "Funding Information: The authors express sincere thanks to Dr. J. Michael Hamilton, Chief of Clinical Investigations Section, NCI-Navy Medical Oncology Branch, Bethesda, Maryland, for his kind help with this manuscript. This work was supported by VGH-82-05 and Chin-Lin Foundation.",

year = "1996",

doi = "10.3109/07357909609012139",

language = "English",

volume = "14",

pages = "197--201",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil

AU - Chiou, Tzeon Jye

AU - Kung, Sung Pao

AU - Hsieh, Ruey Kuen

AU - Fan, San

AU - Tzeng, Cheng Hwai

AU - Wei, Chih Hsin

AU - Chen, Po Min

N1 - Funding Information: The authors express sincere thanks to Dr. J. Michael Hamilton, Chief of Clinical Investigations Section, NCI-Navy Medical Oncology Branch, Bethesda, Maryland, for his kind help with this manuscript. This work was supported by VGH-82-05 and Chin-Lin Foundation.

PY - 1996

Y1 - 1996

N2 - The efficacy and toxicity of a combination of etoposide 100 mg/m2/day iv on day 2-4, leucovorin 300 mg/m2/day iv, and 5-FU 500 mg/m2 day iv on day 1-5 every 4 weeks were assessed in 21 patients with advanced gastric cancer with measurable or evaluable diseases. Eight patients had an objective response, including 3 in CR. The overall response rate was 38.1% (95% CI 33.4-42.8%). Five of 8 patients who exhibited locally advanced and unresectable diseases had an objective response (2 CR, 3 PR). The response rate in patients with metastatic disease was 23.0% (95% CI 14.4-31.6%). The median progression-free interval and overall survival time were 7 and 10 months, respectively. The most frequent side effect was alopecia (Gr I/II 71.4%). No treatment-related death occurred. Modified ELF is a relatively effective and tolerable combination regimen for advanced gastric cancer and can be safely administered to elderly patients and patients with systemic diseases.

AB - The efficacy and toxicity of a combination of etoposide 100 mg/m2/day iv on day 2-4, leucovorin 300 mg/m2/day iv, and 5-FU 500 mg/m2 day iv on day 1-5 every 4 weeks were assessed in 21 patients with advanced gastric cancer with measurable or evaluable diseases. Eight patients had an objective response, including 3 in CR. The overall response rate was 38.1% (95% CI 33.4-42.8%). Five of 8 patients who exhibited locally advanced and unresectable diseases had an objective response (2 CR, 3 PR). The response rate in patients with metastatic disease was 23.0% (95% CI 14.4-31.6%). The median progression-free interval and overall survival time were 7 and 10 months, respectively. The most frequent side effect was alopecia (Gr I/II 71.4%). No treatment-related death occurred. Modified ELF is a relatively effective and tolerable combination regimen for advanced gastric cancer and can be safely administered to elderly patients and patients with systemic diseases.

UR - http://www.scopus.com/inward/record.url?scp=0029762346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029762346&partnerID=8YFLogxK

U2 - 10.3109/07357909609012139

DO - 10.3109/07357909609012139

M3 - Article

C2 - 8630679

AN - SCOPUS:0029762346

SN - 0735-7907

VL - 14

SP - 197

EP - 201

JO - Cancer Investigation

JF - Cancer Investigation

IS - 3

ER -

Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this